[ Rubius Therapeutics raises $120M in Series B Funding ]
Rubius Therapeutics has raised $120 million in Series B Funding.
Founded in 2013, Rubius Therapeutics is developing Red-Cell Therapeutics (RCTs) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
With the fresh money, Rubius is well positioned to focus on the continued development of our platform to advance a broad range of therapeutic candidates that have the potential to make a significant difference in the lives of patients.
|Founder / CEO||Avak Kahvejian|
|Previous Investors||same as above|